Increased interest in cyclodextrins (CDs) in recent years has led to a strong market demand, and several new pharmaceutical products containing beta-cyclodextrins or their derivatives have reached the market succesisfully. To meet the specific needs of the pharmaceutical industry, Roquette now offers a wide range of KLEPTOSE® products: beta-cyclodextrins and HPβCDs.
Roquette, a leader in beta-cyclodextrins (KLEPTOSE®), recently expanded its range by launching KLEPTOSE® HPB-LB – a new grade of modified cyclodextrin: hydroxypropyl-beta cyclodextrin (HPβCD) as an excipient grade for use in parenteral applications. Meeting the highest global purity standards and following the principles of GMP, KLEPTOSE® HPB-LB parenteral grade will facilitate the registration of pharmaceutical products in multiple target markets.
Blouet E, “A New Multi-Compendia Modified Beta-Cyclodextrin, KLEPTOSE® HPB-LB Parenteral Grade”. ONdrugDelivery Magazine, Issue 97 (May 2019), pp 12-15.